Insitro

“What I think we're starting to see right now is a the pendulum starting to swing back in the sense that there is a greater understanding that you really need a bit of both. You need that hugely powerful pattern recognition that we get from deep learning, but y…”

“Look, it's just like GPT, but for cells.”

“What brought me back to this field back in 2016 post Coursera was the realization that we can now finally, for the first time, measure biology at scale, both at the cellular level, sometimes at subcellular level, and at the organism level via ways of quantitat…”

“So one of the things that we have at Insitro that is truly unique is we have a data factory. We have put together the tools that have been developed by people who are taking pluripotent stem cells, which are cells from you or me or anyone in this audience and …”

“When they're all in a pool, you eliminate all of those artifacts, and all of a sudden you have the ability to measure a genome-wide CRISPR screen, basically, so, 20,000 genes in the genome, all modifying the same cellular background in the same dish with a dif…”

“It's impossible to run this instrument without AI being built into it, because you can't even segment the cells. You can't call the barcodes. I mean, all of it is an AI-enabled architecture. Every part of our technology stack is intrinsically AI-enabled.”

“The hope is that by the end of the Of this decade, we will have built this process, we will have run through it a number of times, we will have delivered some medicines to patients in our first tranche of indications, but then we will have learned enough from …”

“And this notion of, you know, we can cure lots of mice is, is something that really drove our discovery strategy at in situ, which is all of our work is done in human and human derived systems.”

“Which is one of the reasons why we spend so much of our time building robots, because they do the same thing over and over again.”

“Which ultimately what we're looking to do is to replace the sort of untranslatable animal models with something that is much more driven from human biology.”

“The other areas that we've gone into are metabolism and oncology, because again, those are areas where relevant, disease relevant data, That is high content, that is unbiased and truly informative about the disease state is collected quite abundantly as part o…”

“There's plenty of things that we can do today where the where the disease does manifest sufficiently in a single cell lineage, and so we go after those first, and we defer some of the other ones to a later stage, because technologies such as organoids, for exa…”

“Maybe in three years we'll have another tranche of diseases that are unlocked by the technological tidal wave that we're all riding.”

“And that can usually say shave off, you know, two, three, maybe even five years from the development of a program because you've already made the drug. Sometimes you've already put it in people. You've shown that it's safe. You have a good biomarker for when i…”

“We have product managers who do scrums and do you know, these agile planning processes, and we apply that also to our platform development, even on the biology side. But at the same time, you know, drug discovery projects, which are years long, you don't do sc…”